Table of Contents

FORM 10-Q



U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



Quarterly Report under Section 13 of the

Securities Exchange Act of 1934



Quarter ended March 31, 2002



Commission File Number 0-24320



NaPRO BIOTHERAPEUTICS, INC.

|Incorporated in Delaware | IRS ID No. 84-1187753
|------------------------ | ---------------------



6304 Spine Road, Unit A
Boulder, CO 80301
(303) 530-3891



NaPro BioTherapeutics, Inc. (1) has filed all reports required to be filed by Section 13 of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days.

The number of shares outstanding of each of the issuer's classes of common stock as of April 26, 2002:

Common Stock, $.0075 par value 29,717,213



Total number of pages in document--16

NaPro BioTherapeutics, Inc.

Table of Contents



> Part I Financial Information

Consolidated Financial Statements

Balance Sheet

Operations Statement

Cash Flow Statement

Notes to Consolidated Financial Statements

Management's Discussion and Analysis of Financial Condition and Results of Operations

Quantitative and Qualitative Disclosures about Market Risk



> Part II Other Information

Legal Proceedings

Changes in Securities

Defaults Upon Senior Securities

Submission of Matters to a Vote of Security Holders

Other Information

Exhibits and Reports on Form 8-K



Part I. Financial Information





> Item 1. Consolidated Financial Statements

> 

|NaPro BioTherapeutics, Inc.
|---------------------------
|Balance Sheet              
|Assets                     
|                           
|                           
|                           
|                           
|                           
|Current assets:            
|                           
|                           
|                           
|                           
|                           
|                           
|                           
|                           
|Total current assets       
|                           
|Property and equipment, net
|Other assets               
|Total assets               
|                           
|                           
|                           
|See accompanying notes.    



|NaPro BioTherapeutics, Inc.                        
|---------------------------------------------------
|Balance Sheet                                      
|Liabilities and Stockholders' Equity               
|                                                   
|                                                   
|                                                   
|                                                   
|Current liabilities:                               
|                                                   
|                                                   
|                                                   
|                                                   
|Total current liabilities                          
|                                                   
|Notes payable--long term                           
|Deferred income--long term                         
|                                                   
|Convertible Debt                                   
|                                                   
|Stockholders' equity:                              
|Preferred stock, $.001 par value:                  
|                                                   
|                                                   
|Non-voting common stock, convertible on disposition
|                                                   
|                                                   
|                                                   
|                                                   
|Common stock, $.0075 par value:                    
|                                                   
|                                                   
|                                                   
|Additional paid-in capital                         
|Accumulated deficit                                
|Treasury stock--54,306 and 254,306 shares at cost  
|in 2002 (unaudited) and 2001                       
|Total stockholders' equity                         
|Total liabilities and stockholders' equity         



See accompanying notes.

NaPro BioTherapeutics, Inc.

|Operations Statement                
|------------------------------------
|(Unaudited)                         
|                                    
|March 31,                           
|                                    
|                                    
|Product sales                       
|                                    
|Expense:                            
|                                    
|                                    
|                                    
|                                    
|Operating loss                      
|                                    
|Other income expense:               
|                                    
|                                    
|                                    
|                                    
|                                    
|Basic and diluted net loss per share
|                                    
|Weighted average shares outstanding 
|                                    
|                                    
|                                    

See accompanying notes.

NaPro BioTherapeutics, Inc.





|Cash Flow Statement                             
|------------------------------------------------
|(Unaudited)                                     
|                                                
|March 31,                                       
|                                                
|Operating activity                              
|Net loss                                        
|Adjustments to reconcile net loss to net cash   
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|Net cash provided (used) by operating activity  
|Investing activity                              
|                                                
|Net cash used by investing activity             
|Financing activity                              
|                                                
|                                                
|                                                
|                                                
|                                                
|                                                
|Net cash provided by financing activity         
|Net increase in cash and cash equivalents       
|Cash and cash equivalents at beginning of period
|Cash and cash equivalents at end of period      
|                                                
|                                                
|                                                
|See accompanying notes.                         









NaPro BioTherapeutics, Inc.





|Cash Flow Statement              
|---------------------------------
|(Unaudited)                      
|                                 
|                                 
|March 31,                        
|                                 
|Supplemental schedule of activity
|                                 
|Interest paid                    
|                                 
|Noncash transactions:            
|                                 
|                                 
|                                 
|                                 
|                                 
|                                 
|See accompanying notes.          
|                                 



NaPro BioTherapeutics, Inc.

Notes to Financial Statements

March 31, 2002

(Unaudited)



1. Basis of Presentation



The accompanying financial statements are unaudited. However, in the opinion of management, the financial statements reflect all adjustments, consisting of only normal recurring adjustments, necessary for fair presentation. Interim results of operations are not indicative of results for the full year. These financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2001.



2. Reclassifications



Certain data in the prior year consolidated financial statements have been reclassified to conform to 2002 presentation.



3. Private Placement



In February 2002 we sold privately $8 million of common stock issued at $9 per share and $8 million principal of five-year 4% debentures convertible into common stock at $15 per share to TL Ventures V, L.P. and one of its affiliated funds. No placement agent was involved in the transaction. Our net proceeds were $15,639,000. We subsequently filed a registration statement with the SEC to register the resale of the shares under the Securities Act of 1933. We may pay the debenture interest in cash or common stock at our option. The debentures automatically convert into common stock during the first two years if the average price of the common stock for 15 trading days is $22, and during the last three years if the average price for 30 trading days is $16. If we have insufficient funds to repay the debentures in full at maturity or upon acceleration, the holders of the debentures may elect to convert the outstanding principal balance and any unpaid accrued interest on the debentures into shares of common stock at a conversion price equal to the then current 20 day average trading price of the common stock. Marc Ostro, one of our directors, is a managing director of an affiliate of the investment manager of the TL Venture Funds, and a voting limited partner in the TL Venture Funds.



4. Approval of Abbreviated New Drug Application, or ANDA



In March 2001 we and Abbott Laboratories filed an ANDA with the U.S. Food and Drug Administration, or FDA. On May 8, 2002 the FDA approved the ANDA.



Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations



The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of the results of operations of NaPro BioTherapeutics, Inc. You should read this discussion in conjunction with the Financial Statements and Notes included elsewhere in this report. Special Note: Certain statements below constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, referred to as the Reform Act. See "Special Note Regarding Forward Looking Statements."



General



We are a biopharmaceutical company focused on the development, production and licensing of complex natural product pharmaceuticals as well as the development and licensing of novel genomic technologies for applications in human therapeutics and diagnostics, pharmacogenomics and agrobiotechnology. Our lead product is paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or Taxus trees. In addition to our efforts with paclitaxel and genomics, we are also working on several types of compounds that have promising activity as anti-cancer agents. We believe some of these agents function by novel mechanisms, which may increase their likelihood of success as new chemotherapeutics. We are also actively engaged in evaluating the in-licensing or purchase of potential new products and/or technologies, whether or not those products or technologies are derived from natural products. Our evaluation of new products and technologies may involve the examination of individual molecules, classes of compounds, or platform technologies, in both cancer and other therapeutic areas. Acquisitions of new products or technologies may involve the purchase of such products or technologies, or the acquisition of, or merger with, other companies.



We continue to incur substantial research and development expense related to the improvement of our paclitaxel yield, the reduction of our long-term cost of product, the development of our semisynthesis process, our genomics research and development, and the development of other drug candidates.  Accordingly, we have incurred significant losses, including losses of $25.8 million, $16.6 million and $9 million for the years ended December 31, 2001, 2000 and 1999, respectively.  We incurred a loss of $6.7 million for the quarter ended March 31, 2002, resulting in an accumulated deficit of $101.7 million as of March 31, 2002.  We expect that we will continue to run at these operating expense levels.  We anticipate that losses may continue until such time, if ever, as we are able to generate sufficient sales to support our development operations, including the expanded research and development activity mentioned above.



Our ability to generate sufficient sales to support our operations depends primarily upon the successful commercialization of our worldwide paclitaxel program.  Our strategy for that program has been to form strategic alliances through long-term exclusive agreements with major pharmaceutical companies.  In 1999 we entered into an exclusive collaborative agreement of up to 20 years covering the U.S. and Canada with Abbott Laboratories to develop and commercialize one or more formulations of paclitaxel for the treatment of a variety of cancers.  Under our agreement with Abbott, we are responsible for supply of bulk drug; development activity is conducted jointly.  Abbott is responsible for finishing, regulatory filings, marketing, and sale of the finished drug product.  Most primary decisions related to the paclitaxel development program are made by a joint Abbott-NaPro Development Committee.  In March 2001 we and Abbott filed an Abbreviated New Drug Application, or ANDA, with the U.S. Food and Drug Administration, or FDA, for paclitaxel.  The FDA granted approval of this ANDA on May 8, 2002.



We received an initial $1 million development milestone payment from Abbott in July 1999. Contingent upon our successful achievement of all development milestones, we could receive up to an additional $29 million in development milestone payments. With the approval of our ANDA, and upon commencement of commercial sales, we will receive $8 million of the $29 million. Additional development milestones will only be available on new indications approved for the current or another formulation of paclitaxel, resulting from new development work.



We have received $20 million of secured debt from Abbott. The debt bears a primary interest rate of 6.5% and is due in full on the earlier of: (i) the second anniversary of the first sale of finished product by Abbott to a wholesaler or end-user customer following approval of finished product by the FDA; (ii) the termination of the Abbott agreement; or (iii) January 1, 2007. The debt is limited to a borrowing base of collateralized assets, recomputed monthly. The majority of our hard assets are pledged as security for the debt.



Contingent upon achieving certain commercial sales thresholds for all approved formulations of paclitaxel over several years, we may receive marketing milestone payments from Abbott of up to $57 million. We cannot assure that sales thresholds necessary to trigger any of the future milestone payments will be achieved.



Under terms of the agreement, Abbott purchases bulk drug from us. As Abbott sells the paclitaxel product, Abbott will pay a percentage of its net paclitaxel sales to us, less Abbott's payments for purchase of bulk drug. Abbott may terminate the agreement at any time with or without cause. Should Abbott terminate without cause, it is obligated to make payments to us.



In 1992 we entered into a 20-year exclusive agreement with F.H. Faulding & Co., Ltd., a large Australian pharmaceutical company, for the clinical development, sale, marketing and distribution of paclitaxel. Faulding actively markets anti-cancer pharmaceuticals and other health care products in Europe, Australia, Asia, South America, and other regions throughout the world. In 2000, we amended the Faulding agreement to, among other things, add additional countries to Faulding's exclusive territory. In 2001 we entered into a separate agreement with Faulding covering development and sale of paclitaxel in Europe. Including the new agreement for Europe, the Faulding territory includes substantially all of the world other than the U.S., Canada, Japan, Israel, the former Soviet Union and parts of Africa. Faulding has received marketing approval for, and is selling paclitaxel as ANZATAX(TM) in more than 25 countries.



In Europe, we are responsible for regulatory filings and will supply paclitaxel exclusively to Faulding to formulate and finish the product. We cannot assure that we will receive regulatory approval in Europe. Should we receive approval, Faulding will then market and sell the final proprietary paclitaxel formulation in Europe. We will share equally the net sales of the product in Europe.



In October 2001, Faulding was acquired by Mayne-Nickless Limited, an Australian based health care provider and logistics operator. Although Faulding continues to operate as a wholly-owned subsidiary of Mayne-Nickless, Mayne-Nickless has in the past indicated that it may sell the pharmaceutical business of Faulding, including Faulding's paclitaxel sales and marketing operations. We are uncertain what effect, if any, the change of ownership of Faulding will have on our business, financial condition and results of operations.



In January 2001 we received approval in Israel to sell paclitaxel under the trade name Biotax(TM). We have established an exclusive supply and distribution agreement with Tzamal Pharma for the development and distribution of paclitaxel in Israel. The Israeli Ministry of Health has approved Biotax for use in treating a variety of cancers.



In June 2001 we and JCR Pharmaceuticals Co., Ltd. entered into a mutually exclusive development, supply and distribution agreement for paclitaxel in Japan. Under the agreement, we will be responsible for manufacturing and supplying the finished drug. JCR and we will jointly be responsible for the clinical and regulatory program necessary for seeking approval to market paclitaxel in Japan. JCR will fund the clinical and regulatory program. JCR will be responsible for the sales and distribution of the product in Japan upon its approval.



In anticipation of final FDA approval for commercial sales, we have substantially expanded, and continue to expand, our existing manufacturing facilities. We cannot assure, however, that we will receive regulatory approval of paclitaxel (in Europe or Japan) or that we and our strategic partners will successfully market it. We anticipate financing the construction and expansion with new capital, either in the form of debt or otherwise, if available on acceptable terms, although we cannot assure that we will be able to do so.



Research and Development



Development and research are major focuses for us. We discussed the nature and status of our development and research in depth in our December 31, 2001 Form 10-K annual report in Item 1-Business, in the General, Paclitaxel Overview, Paclitaxel Development, Biomass, Manufacturing, Strategic Alliances, Competition, Patents and Proprietary Technology, Government Regulation and Product Approvals, and Research and Development sections, and in the General section of this Management's Discussion and Analysis.



We have incurred the following expense on research and development projects:





|         | Quarter Ended March 31
|-------- | ----------------------
|         | 2002                  
|Oncology | $2,574,000            
|Genomics | 897,000               
|         | $3,471,000
========   



Our development and research activity is subject to change as we develop a better understanding of our projects and their prospects. Accordingly, we cannot estimate the timing or the cost of the effort necessary to complete the projects, the estimated completion dates or the timing of commencement of material net cash inflows from the projects. We have included the risks and uncertainties associated with completing development on schedule in the Special Note Regarding Forward-looking Statements, below.



Results of Operations



Quarter ended March 31, 2002, compared to the quarter ended March 31, 2001. Sales for the 2002 quarter were $6.7 million, an increase of $2.8 million from the 2001 quarter. Sales to Abbott in the 2002 quarter increased $2.8 million from the 2001 quarter.



Cost of products sold for the 2002 quarter was $7.1 million, an increase of $4.1 million from the 2001 quarter. The increase was attributable to a 152% increase in volume ($2.7 million), plant downtime resulting from the start-up of a third party extraction vendor ($1.3 million) and a number of other increases ($1.3 million), partially offset by a decrease in unit production cost ($1.2 million).



Research and development expense for the 2002 quarter was $3.5 million, an increase of $2.2 million from the 2001 quarter. Genomics research and development increased $900,000, and oncology research and development increased $1.3 million.



General and administrative expense for the 2002 quarter was $2.9 million, an increase of $1.1 million from the 2001 quarter. Legal expense increased $600,000 and payroll and benefits increased $700,000.



License fee income for the 2002 quarter was $400,000, an increase of $300,000 from the 2001 quarter. License fee income represents amortization of license fees received in March and June 2001 in connection with the Faulding European agreement and JCR Pharmaceuticals Japanese agreement, respectively.



Interest income for the 2002 quarter was $100,000, a decrease of $200,000 from the 2001 quarter. The decrease was attributable to lower average balances of interest-bearing investments ($100,000) and lower interest rates ($100,000).



Interest expense for the quarter was $400,000, an increase of $100,000 from the 2001 quarter. The increase was attributable to the issuance of $8 million in convertible debt during the 2002 quarter and a $5 million increase in the Abbott loan after the 2001 quarter.



Liquidity and Capital Resources



Our capital requirements have been and will continue to be significant. As of March 31, 2002, we had a working capital balance of $23.7 million compared to a working capital balance of $13.6 million as of December 31, 2001. To date, we have funded our capital requirements primarily with the net proceeds of public offerings of common stock of approximately $21.1 million, with private placements of equity securities of approximately $62.7 million, with the exercise of warrants and options of $7.9 million and with net borrowing of $27.7 million.



In February 2002 we sold privately $8 million of common stock issued at $9 per share and $8 million principal value of five-year 4% debentures convertible into common stock at $15 per share. No placement agent was involved in the transaction. Our net proceeds were
$15,639,000. We subsequently filed a registration statement with the SEC to register the resale of the shares under the Securities Act of 1933. We may pay the debenture interest in cash or common stock at our option. The debentures automatically convert into common stock during the first two years if the average price of the common stock for 15 trading days is $22, and during the last three years if the average price for 30 trading days is $16. If we have insufficient funds to repay the debentures in full at maturity or upon acceleration, the holders of the debentures may elect to convert the outstanding principal balance and any unpaid accrued interest on the debentures into shares of common stock at a conversion price equal to the then current 20 day average trading price of the common stock. The conversion price of the common stock in such a circumstance could be materially below the price at which we otherwise would be willing to issue our common stock. Issuance of common stock at such a price could result in substantial dilution to our other stockholders and could have a material adverse effect on the market price of our common stock.



We believe existing capital and projected 2002 sales will provide adequate capital to fund our operations and capital expenditures in 2002. However, pharmaceutical development is a costly and time consuming process. We may in-license or purchase new products or technologies. The cost of acquiring and developing such resources, and related capital expenditures, may be very large. As a result, we may seek additional capital. We cannot assure that we will be able to obtain such capital.



Working Capital and Cash Flow Cash and cash equivalents increased $7.9 million to $18 million for the quarter ended March 31, 2002, from $10.1 million at December 31, 2001. During the 2002 quarter net cash provided by financing activity of $15.9 million was offset by investment activity of $1.9 million and cash used by operations of $6.2 million.



Accounts receivable increased $600,000 to $4.3 million for the quarter ended March 31, 2002, from $3.7 million at December 31, 2001 because of increased sales. NaPro anticipates that it may utilize significant working capital to fund accounts receivable should sales continue to increase.



Inventory was $8.6 million at March 31, 2002. The amount of inventory is dependent on a number of factors, including the shipping requirements of our strategic partners, our production planning for meeting those needs, and the timing of biomass harvests. Inventory balances may vary significantly during product development and launch periods.



Capital Expenditures We spent $1.9 million during the 2002 quarter for capital projects. These expenditures primarily included expansion of our manufacturing and other facilities, plantation cost and laboratory equipment. We anticipate additional expenditures in the near term, particularly for expansion of manufacturing facilities.



The amount and timing of future capital expenditures will depend upon numerous factors, including:



the cost of manufacturing expansion for paclitaxel;

the development of new products;

the acquisition of new products or technologies;

the cost of manufacturing resources for new products;

the nature of our relationship with our strategic partners;

the progress of our research and development programs;

changes in manufacturing processes;

the magnitude and scope of these activities;

competing technological and marketing developments; and

changes in or terminations of existing strategic relationships.

> 

In 2002 we anticipate significant expenditures for improving efficiency and expanding capacity at our existing facilities. The expanded scope of our research and development activity will require significant additions to laboratory equipment. All of these factors, and others, lead us to expect a continued high level in capital expenditures in 2002. Although we may seek additional long-term financing to fund the increases in capital expenditures, we cannot assure that we can obtain such financing on terms which are acceptable to us.



Net Operating Loss Carryforwards As of December 31, 2001, we had approximately $82 million of net operating loss carryforwards to offset future taxable income. Tax law provides limits on the utilization of net operating loss carryforwards if there has been a "change of ownership" as described in Section 382 of the Internal Revenue Code. Such a change of ownership may limit our utilization of our net operating loss carryforwards, and could be triggered by sales of securities by us or our stockholders.

Special Note Regarding Forward-looking Statements

This report contains forward-looking statements that involve known and unknown risks, including, without limitation, statements containing the words "believes", "anticipates", "estimates", "may" and words of similar import or statements of management's opinion or statements that are not historical fact. In addition, our representatives from time to time may orally make forward looking statement. Such forward-looking statements may include, among others:

statements concerning our plans, objectives and future economic prospects, such as matters relative to developing new products;

the availability of patent and other protection for our intellectual property;

the completion of preclinical studies, clinical trials and regulatory filings;

the prospects for, and timing of, regulatory approvals;

the need and plans for, and availability of, additional capital;

the amount and timing of capital expenditures;

the timing of product introductions and sales;

the availability of raw materials;

prospects for future operations; and

other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among other things, the following:

the inability to obtain European or Japanese regulatory approvals for paclitaxel or a delay in such approvals;

competition from Bristol-Myers Squibb Company, Ivax Corporation, Aventis S.A., Mylan Laboratories, Inc., and other producers of paclitaxel and other drugs;

technological advances in cancer treatment and drug development that may obsolesce paclitaxel;

the risks associated with patent litigation;

the ability to obtain rights to technology;

the ability to obtain, maintain and enforce patents;

the ability to maintain trade secrets;

the ability to obtain raw materials and commercialize manufacturing processes;

the effectiveness of other pharmaceuticals we develop in treating disease;

the results of preclinical and clinical studies;

the results of research and development activities;

the ability to purchase or license new products;

the successful development of new products;

the business abilities and judgment of our management and other personnel;

the ability to hire skilled personnel to perform research and development and to run our manufacturing operations;

the ability of contract manufacturers to perform adequately under anticipated contracts;

the decision-making processes of regulatory agencies;

changes in and compliance with governmental regulations;

the effect of capital market conditions and other factors on capital availability;

the ability of Abbott, Faulding, Tzamal and JCR to perform their obligations under their existing agreements with us;

our ability to perform our obligations under our existing and future agreements;

our limited relevant operating history upon which an evaluation of our prospects can be made;

the effect on sales, cash flow and earnings from foreign exchange rate fluctuations;

adverse economic and general business conditions;

and other factors referenced in this report.

These factors are not intended to be an all-inclusive enumeration of the business risks we face. Reference is also made to the risk factors discussed in Amendment No. 2 to our Registration Statement (No. 333-82810) filed with the Securities and Exchange Commission on April 30, 2002. The forward-looking statements included in this report represent our view as of the date of this report. The reader should not assume that the statements made herein remain accurate at any future date. We do not intend to update these statements and undertake no duty to any person to make any update under any circumstance.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

During 2001, we sold a significant amount of paclitaxel to Faulding. Under the Faulding agreement, Faulding pays us a fixed percentage of their sales price for paclitaxel. Each year, Faulding estimates the sales price it will receive in the upcoming year, and, based upon that estimate, we determine the price we will charge Faulding. We recognize the corresponding sales at the time of shipment to Faulding. However, Faulding's actual selling price may differ from that estimated. In the summer, Faulding provides us with their calculation of the actual sales price for sales made during the preceding year, and an adjustment is calculated that may increase or decrease our sales of products to Faulding during that year.

Faulding's sales are made in the currencies of each of the countries in which it sells paclitaxel. As a result, our sales are affected by fluctuations in the value of these various foreign currencies relative to the U.S. dollar. In the past, currency fluctuations were a significant factor in reductions in the price we charged Faulding. If changes in foreign currency markets continue to cause a decrease in the price per gram we receive from Faulding, there could be a material adverse effect on our earnings and cash flow. Our sales to JCR, if any, are subject to the same risk.

Certain statements in this Item 3 may constitute "forward-looking statements". See "Special Note Regarding Forward-looking Statements."



Part II--Other Information

Item 1. Legal Proceedings.None

Item 2. Changes in Securities.

On February 13, 2002 we issued $8 million of common stock issued at $9 per share and $8 million of 4% convertible subordinated debentures that are convertible into common stock at $15 per share (subject to adjustment for dividends on our common stock, for stock splits, combinations and reclassifications and for the issuance of certain rights or warrants to the holders of our common stock). No placement agent was involved in the transaction. The issuance of the common stock and the debentures was exempt from registration under Section 4(2) of the Securities Act of 1933, as amended, and Regulation D thereunder as a privately negotiated transaction with an accredited investor.

We may pay interest on the debentures in cash or common stock at our option. The debentures automatically convert into common stock during the first two years if the average price of the common stock for 15 trading days is $22, and during the last three years if the average price for 30 trading days is $16. If we have insufficient funds to repay the debentures in full at maturity or upon acceleration, the holders of the debentures may elect to convert the outstanding principal balance and any unpaid accrued interest on the debentures into shares of common stock at a conversion price equal to the then current 20 day average trading price of the common stock.

Item 3. Defaults upon Senior Securities. None

Item 4. Submission of Matters to a Vote of Securities Holders. None

Item 5. Other Information. None

Item 6. Exhibits and Reports on Form 8-K.

We filed a Current Report on Form 8-K dated February 14, 2002 reporting the private sale of $16,000,000 of securities.





Signatures





Pursuant to the requirements of the Securities Exchange Act of 1934, we have duly caused this report to be signed on our behalf.







|             | NaPro BioTherapeutics, Inc.                                                                                                       
|------------ | ----------------------------------------------------------------------------------------------------------------------------------
|May 13, 2002 | /s/ Leonard P. Shaykin
Leonard P. Shaykin
Chairman of the Board of Directors
Chief Executive Officer
(Principal Executive Officer)
|May 13, 2002 | /s/ Gordon Link
Gordon Link
Vice President and Chief Financial Officer
(Principal Financial Officer)                              
|May 13, 2002 | /s/ Robert L. Poley
Robert L. Poley
Controller
(Principal Accounting Officer)